BiotechTube

Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

BRAF V600E-mutant Metastatic Colorectal Cancer

Conditions

BRAF V600E-mutant Metastatic Colorectal Cancer

Trial Timeline

Oct 13, 2016 → Nov 10, 2022

NCT ID
NCT02928224

About Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil

Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil is a phase 3 stage product being developed by Ono Pharmaceutical for BRAF V600E-mutant Metastatic Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02928224. Target conditions include BRAF V600E-mutant Metastatic Colorectal Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02928224Phase 3Completed

Competing Products

13 competing products in BRAF V600E-mutant Metastatic Colorectal Cancer

See all competitors
ProductCompanyStageHype Score
PLX3397 + vemurafenibDaiichi SankyoPhase 1
33
TMZ + E7016EisaiPhase 2
52
encorafenib + Binimetinib + CetuximabOno PharmaceuticalPhase 2
52
Encorafenib + Cetuximab + FOLFIRIMerckPhase 2
52
Tafinlar/MekinistNovartisPre-clinical
23
BKM120 Combined with Vemurafenib (PLX4032)NovartisPhase 1/2
41
Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + TislelizumabNovartisPhase 1
33
Cobimetinib + Atezolizumab + PembrolizumabRochePhase 3
77
LGX818 + MEK162 + LEE011PfizerPhase 1/2
40
MEK162PfizerPhase 2
51
Encorafenib + Binimetinib + cemiplimab+fianlimabRegeneron PharmaceuticalsPhase 2
51
Plixorafenib + Cobicistat 150 MG [Tybost]Brain BiotechPhase 1
25
Dabrafenib + Trametinib + HydroxychloroquineBrain BiotechPhase 1/2
33

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved
85
Abatacept + Placebo matching with Abatacept + MethotrexateApproved
85
Rivastigmine transdermal patchApproved
85
Sitagliptin phosphatePhase 3
77
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3
77